55.57
0.46 (0.84%)
| Previous Close | 55.10 |
| Open | 54.72 |
| Volume | 171,419 |
| Avg. Volume (3M) | 695,770 |
| Market Cap | 5,121,159,168 |
| Price / Sales | 9.70 |
| Price / Book | 12.30 |
| 52 Weeks Range | |
| Earnings Date | 31 Oct 2024 - 4 Nov 2024 |
| Profit Margin | -121.57% |
| Operating Margin (TTM) | -79.14% |
| Diluted EPS (TTM) | -7.21 |
| Quarterly Revenue Growth (YOY) | 35.70% |
| Total Debt/Equity (MRQ) | 214.27% |
| Current Ratio (MRQ) | 3.54 |
| Operating Cash Flow (TTM) | -469.47 M |
| Levered Free Cash Flow (TTM) | -275.98 M |
| Return on Assets (TTM) | -23.42% |
| Return on Equity (TTM) | -208.43% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Ultragenyx Pharmaceutical Inc. | Bullish | Bullish |
Stockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 3.63% |
| % Held by Institutions | 99.22% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Alkeon Capital Management Llc | 30 Jun 2024 | 2,241,832 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 116.00 (Cantor Fitzgerald, 108.77%) | Buy |
| Median | 76.50 (37.68%) | |
| Low | 46.00 (Wedbush, -17.21%) | Hold |
| Average | 83.50 (50.27%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 51.39 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 01 Oct 2024 | 116.00 (108.76%) | Buy | 56.51 |
| 20 Sep 2024 | 116.00 (108.76%) | Buy | 58.75 | |
| RBC Capital | 26 Sep 2024 | 77.00 (38.58%) | Buy | 55.22 |
| Goldman Sachs | 02 Aug 2024 | 76.00 (36.78%) | Buy | 50.47 |
| Wedbush | 02 Aug 2024 | 46.00 (-17.21%) | Hold | 50.47 |
| 18 Jul 2024 | 45.00 (-19.01%) | Hold | 42.78 | |
| Wells Fargo | 02 Aug 2024 | 75.00 (34.98%) | Buy | 50.47 |
| Canaccord Genuity | 23 Jul 2024 | 111.00 (99.77%) | Buy | 45.18 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |